Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Relay Therapeutics Inc (RLAY)

Relay Therapeutics Inc (RLAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,814,069
  • Shares Outstanding, K 178,726
  • Annual Sales, $ 15,360 K
  • Annual Income, $ -276,480 K
  • EBIT $ -303 M
  • EBITDA $ -302 M
  • 60-Month Beta 1.55
  • Price/Sales 114.65
  • Price/Cash Flow N/A
  • Price/Book 3.01

Options Overview Details

View History
  • Implied Volatility 349.88% (+37.01%)
  • Historical Volatility 75.07%
  • IV Percentile 78%
  • IV Rank 42.90%
  • IV High 759.75% on 09/12/25
  • IV Low 41.91% on 04/04/25
  • Expected Move (DTE 15) 2.00 (20.70%)
  • Put/Call Vol Ratio 0.54
  • Today's Volume 37
  • Volume Avg (30-Day) 157
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 3,464
  • Open Int (30-Day) 2,973
  • Expected Range 7.65 to 11.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.36
  • Number of Estimates 6
  • High Estimate -0.20
  • Low Estimate -0.45
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +21.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.33 +15.73%
on 02/06/26
11.43 -15.63%
on 02/27/26
+1.49 (+18.28%)
since 02/05/26
3-Month
7.01 +37.52%
on 01/20/26
11.43 -15.63%
on 02/27/26
+1.96 (+25.52%)
since 12/05/25
52-Week
1.77 +444.63%
on 04/07/25
11.43 -15.63%
on 02/27/26
+6.25 (+184.37%)
since 03/05/25

Most Recent Stories

More News
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones

Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced...

RLAY : 9.71 (-4.33%)
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 9.71 (-4.33%)
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 9.71 (-4.33%)
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 9.71 (-4.33%)
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer

Designation supported by robust clinical  data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib...

RLAY : 9.71 (-4.33%)
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025

Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with...

RLAY : 9.71 (-4.33%)
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates

Continued focused execution of RLY-2608 clinical trials in PI3Kα-mutated  breast cancer and vascular malformations Appointed Lonnel Coats and Habib Dable, former biotech CEOs with launch and commercialization...

RLAY : 9.71 (-4.33%)
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 9.71 (-4.33%)
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge...

RLAY : 9.71 (-4.33%)
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...

RLAY : 9.71 (-4.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Relay Therapeutics Inc. is a clinical-stage precision medicines company. It focuses on enhancing small molecule therapeutic discovery in targeted oncology. The company's product pipeline consist RLY-1971, RLY-4008 and RLY-PI3K1047 which are in clinical stage. Relay Therapeutics Inc. is based in Cambridge,...

See More

Key Turning Points

3rd Resistance Point 11.12
2nd Resistance Point 10.68
1st Resistance Point 10.42
Last Price 9.71
1st Support Level 9.72
2nd Support Level 9.28
3rd Support Level 9.02

See More

52-Week High 11.43
Last Price 9.71
Fibonacci 61.8% 7.74
Fibonacci 50% 6.60
Fibonacci 38.2% 5.46
52-Week Low 1.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar